Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)
Recruiting · NCT06927024 · Interventional (participants receive a specific treatment) · Lead sponsor: NYU Langone Health
View the official record on ClinicalTrials.gov →Interventions studied
Active taVNSSham taVNS
What this trial is about
30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Individuals age ≥18 years
- Diagnosis of Chronic Kidney Disease (CKD) stage 3-5 \[estimated glomerular filtration rate \≤60 mL/min/1.73m2\]
- Receiving care at NYU Nephrology outpatient practice
- Able to provide informed consent
Exclusion criteria
- Primary ANS disorders (e.g., Parkinson's disease)
- Arrhythmias
- Implantable cardioverter-defibrillator (ICD) or pacemaker (PPM) precluding assessment of HRV (e.g., chronic atrial fibrillation)
- On maintenance dialysis (HD)
- Epilepsy
- Symptomatic bradycardia
- Presence of an implantable defibrillators
- Presence of a permanent pacemaker
- Unable to consent
- Incarcerated individuals
- Pregnant individuals
Where it is running
1 location listed across 1 US state.
- NYU Langone Health - New York, New York, United States